Answer
Kisunla (donanemab) is contraindicated in people with serious hypersensitivity to donanemab or any of its excipients.
Sources for this answer
- Kisunla 350 mg concentrate for solution for infusionEli Lilly and Company Limited · emc · SmPC §4.3 Contraindications · Version 3Document updated
Sources checked